GSA Capital Partners LLP Purchases Shares of 826 Medpace Holdings, Inc. (NASDAQ:MEDP)

GSA Capital Partners LLP acquired a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 826 shares of the company’s stock, valued at approximately $276,000.

Other institutional investors have also recently made changes to their positions in the company. Ashton Thomas Securities LLC purchased a new position in Medpace in the third quarter valued at $37,000. DT Investment Partners LLC acquired a new position in Medpace in the 2nd quarter worth about $41,000. Capital Performance Advisors LLP purchased a new position in Medpace during the third quarter worth approximately $46,000. Ashton Thomas Private Wealth LLC acquired a new stake in Medpace in the second quarter valued at approximately $52,000. Finally, EntryPoint Capital LLC purchased a new stake in shares of Medpace in the first quarter valued at approximately $54,000. 77.98% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages recently commented on MEDP. StockNews.com lowered shares of Medpace from a “buy” rating to a “hold” rating in a report on Friday, September 27th. Baird R W cut shares of Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. Truist Financial decreased their price target on shares of Medpace from $415.00 to $397.00 and set a “hold” rating on the stock in a research note on Monday, October 14th. Jefferies Financial Group lowered Medpace from a “buy” rating to a “hold” rating and cut their price objective for the stock from $415.00 to $345.00 in a research note on Wednesday, September 25th. Finally, Redburn Atlantic initiated coverage on Medpace in a research report on Monday, October 14th. They set a “buy” rating and a $404.00 price target for the company. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, Medpace has a consensus rating of “Hold” and a consensus target price of $380.00.

Medpace Trading Down 1.2 %

Shares of MEDP opened at $337.75 on Friday. Medpace Holdings, Inc. has a 12-month low of $268.80 and a 12-month high of $459.77. The firm has a market capitalization of $10.50 billion, a P/E ratio of 29.58, a P/E/G ratio of 1.89 and a beta of 1.37. The firm has a 50-day moving average price of $340.14 and a 200 day moving average price of $373.33.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Monday, October 21st. The company reported $3.01 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.24. Medpace had a net margin of 17.66% and a return on equity of 50.87%. The business had revenue of $533.32 million during the quarter, compared to analysts’ expectations of $540.99 million. During the same quarter in the prior year, the company posted $2.22 EPS. The business’s revenue for the quarter was up 8.3% on a year-over-year basis. Equities research analysts predict that Medpace Holdings, Inc. will post 11.93 earnings per share for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.